Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.

Tytuł:
Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.
Autorzy:
Sung L; The Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Aplenc R; Division of Pediatric Oncology/Stem Cell Transplant, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Alonzo TA; Children's Oncology Group, Monrovia, CA, USA.; Department of Biostatistics, University of Southern California, Los Angeles, CA, USA.
Gerbing RB; Children's Oncology Group, Monrovia, CA, USA.
Wang YC; Children's Oncology Group, Monrovia, CA, USA.
Meshinchi S; Division of Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gamis AS; Department of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.
Źródło:
International journal of cancer [Int J Cancer] 2016 Nov 01; Vol. 139 (9), pp. 1930-5. Date of Electronic Publication: 2016 Jul 04.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Język:
English
Imprint Name(s):
Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Leukemia, Myeloid, Acute/*drug therapy
Neutropenia/*chemically induced
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Recurrence ; Remission Induction ; Risk Factors ; Treatment Outcome
References:
Br J Haematol. 2009 Oct;147(1):125-8. (PMID: 19663826)
Pharmacogenomics J. 2013 Aug;13(4):335-41. (PMID: 22584460)
J Cancer Res Clin Oncol. 2013 Mar;139(3):419-27. (PMID: 23143606)
Blood. 2007 Nov 15;110(10):3532-9. (PMID: 17660380)
Pharmacogenomics. 2009 Nov;10(11):1839-51. (PMID: 19891558)
Blood. 1996 Jun 15;87(12):4979-89. (PMID: 8652810)
Cancer Sci. 2013 Aug;104(8):1074-82. (PMID: 23648065)
Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):447-50; discussion 451. (PMID: 18064639)
Leukemia. 2004 Jan;18(1):72-7. (PMID: 14586478)
Br J Haematol. 2011 Nov;155(3):366-76. (PMID: 21902686)
Pharmacogenomics. 2012 Feb;13(3):269-82. (PMID: 22304580)
Pharmacogenet Genomics. 2013 Jan;23 (1):29-33. (PMID: 23188068)
J Clin Oncol. 2014 Sep 20;32(27):3021-32. (PMID: 25092781)
Pharmacogenomics. 2012 Aug;13(11):1257-69. (PMID: 22920396)
Grant Information:
U10 CA098543 United States CA NCI NIH HHS; U10 CA180899 United States CA NCI NIH HHS; UG1 CA189955 United States CA NCI NIH HHS
Contributed Indexing:
Keywords: acute myeloid leukemia; neutropenia; oncology; pediatric; relapse risk
Entry Date(s):
Date Created: 20160618 Date Completed: 20170501 Latest Revision: 20181113
Update Code:
20240104
PubMed Central ID:
PMC4990479
DOI:
10.1002/ijc.30236
PMID:
27312107
Czasopismo naukowe
Objective was to describe the relationship between the number of sterile site infections and duration of neutropenia during the first four cycles of chemotherapy and the risk of recurrence and overall survival in children with newly diagnosed acute myeloid leukemia (AML). AAML0531 was a Children's Oncology Group randomized phase 3 clinical trial that included 1022 children with de novo AML. For this analysis, we focused on non-Down syndrome favorable and standard risk patients who completed at least 4 cycles of chemotherapy without recurrence or withdrawal during protocol therapy. Those receiving hematopoietic stem cell transplantation in first remission were excluded. Five hundred and sixty-nine patients were included; 274 (48.2%) were favorable risk. The median cumulative time with neutropenia between Induction II to completion of Intensification II was 96 (range 54-204) days. Number of sterile site infections did not influence the risk of relapse or overall survival. However, longer duration of neutropenia was associated with a lower risk of relapse (hazard ratio 0.81 per 20 days neutropenia, p = 0.007). Longer duration of neutropenia was associated with a reduced risk of relapse for children with favorable and standard risk AML. Toxicity may be influenced by pharmacogenomics suggesting that individualized chemotherapy dosing may be an effective strategy.
Competing Interests: None to declare
(© 2016 UICC.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies